US Approval For Peanut Allergy Therapy Palforzia
Restrictions Could Limit Uptake
Executive Summary
Aimmune has secured approval for the first ever peanut allergy treatment, but safety, cost and administration issues could limit the drug's uptake.
You may also be interested in...
Nestlé Ponders Least Painful Exit From Peanut Allergy Misfire
Heralded as a potential blockbuster, Nestlé's acquisition of Palforzia has proved to be a very expensive mistake.
England’s NICE Okays First Ever Peanut Allergy Treatment Palforzia
Aimmune Therapeutics secures agreement with NHS for “step change” in treating peanut allergy.
Spotlight On Novartis's Latest Potential Breakthrough Treatments
Last week, the Swiss major gave a glimpse into the next wave of innovation coming out of its labs in key areas such as osteoarthritis, pancreatic cancer and food allergy. Scrip has been taking a detailed look at the highlights.